Featured Research

from universities, journals, and other organizations

Researchers Find A Mechanism By Which Cells Resist Chemotherapy

Date:
March 5, 2007
Source:
Universitat Autonoma de Barcelona
Summary:
A team of researchers from the Universitat Autonoma de Barcelona has identified one of the mechanisms used by cancer cells to resist chemotherapy. This discovery, published in the EMBO Jorunal, will make it possible to develop strategies to make tumors more vulnerable to chemotherapy.

The FANCD2 protein accumulates where there is DNA dammage in order to repair it. (Credit: Image courtesy of Universitat Autonoma de Barcelona)
Credit: Image courtesy of Universitat Autonoma de Barcelona

A team of researchers from the UAB's Mutagenesis Group, led by Dr. Jordi Surralés, has identified one of the mechanisms used by cancer cells to resist chemotherapy. This discovery, published in the EMBO Jorunal, will make it possible to develop strategies to make tumors more vulnerable to chemotherapy.

In his paper, to be published in The EMBO Jorunal, Dr Surrallés describes how proteins of the Fanconi/BRCA pathway recognise the presence of genetic mutations in order to repair them. The researchers also found that alteration of this mechanism makes tumour cells much more sensitive to certain drugs. This discovery will make it possible to develop strategies to make tumours more vulnerable to chemotherapy.

One of the main mechanisms responsible for repairing mutations in humans is the cancer-suppressing Fanconi anaemia/BRCA pathway. This mechanism makes it possible for the cells to identify genetic mutations in order to correct them.

If this mechanism does not function correctly, it leads to Fanconi anaemia, a rare genetic disorder characterised by progressive bone-marrow failure, various congenital malformations and a very high risk of cancer.

Furthermore, the proteins of this pathway are largely responsible for the resistance of tumours to many antitumour agents such as cisplatin and other chemotherapeutic agents that kill tumour cells by producing DNA interstrand crosslinks. That is, they identify cellular alterations induced by chemotherapy and correct them, "accidentally" helping the tumour.

Many tumours have molecular anomalies in this pathway. These defects mean the tumours can be treated efficiently using certain antitumour agents. There are at least 13 genes involved in the pathway. Three of these (BRCA2, BRIP1 and PALB2) are responsible for the high proportion of hereditary breast cancers (between 5 and 10% of all breast cancers).

Understanding how this DNA repair pathway works is of great interest to biomedicine, not only for Fanconi anaemia patients, but also for the general cancer population, since it determines the the efficacy of chemotherapy in treating many tumours. However, the involvement of 13 genes in the same pathway makes the study more complexed.

A team of researchers from the UAB's Mutagenesis Group, led by Doctor Jordi Surralés, has identified one of the important unresolved questions regarding this pathway: how the Fanconi anaemia proteins detect the presence of mutations so they can repair them.

The researchers have found that the mutations block the DNA replication process, a process that is necessary, especially in tumour tissues, for the cells to be able to divide and proliferate. By blocking the replication process, the mutations activate a type of enzyme, the ATR kinase, which phosphorylates (introduces phosphate groups into) histone H2AX, a protein present in the chromatin that surrounds the damaged DNA. The phosphorylated histone H2AX indicates the location of the genetic damage to the Fanconi proteins and places them in exactly the right place to repair the DNA.

The researchers have shown that one of the 13 Fanconi proteins, the FANCD2, binds directly to the phosphorylated histone H2AX. The BRCA1 protein also plays a part in this process and, alongside the BRCA2, it is involved in most hereditary breast cancers. So these proteins cooperate in repairing the genetic damage, preserving the stability of the chromosomes and preventing the onset of tumours.

This research will have many implications on biomedicine. The increase in knowledge on this pathway will make it possible to design strategies for the chemosensitisation of tumour cells. Dr Jordi Surallés's team has also observed that many breast cancer cell lines are between two to three times more sensitive to chemotherapy if they have partially inhibited the Fanconi FANCD2 gene expression.

The results of this study, carried out entirely within the UAB Department Of Genetics and Microbiology, will be published in The EMBO Journal. Most of the work was carried out by the post-doctoral researchers Massimo Bogliolo and Alex Lyakhovich. The group directed by Dr Jordi Surallés is funded by the EU commission, the FEDER fund, the Spanish Ministry of Education and Science, the Spanish Ministry of Health and Consumption, Fundación La Caixa, Genoma España and the Centro de Investigación Biomédica en Red en Enfermedades Raras.


Story Source:

The above story is based on materials provided by Universitat Autonoma de Barcelona. Note: Materials may be edited for content and length.


Cite This Page:

Universitat Autonoma de Barcelona. "Researchers Find A Mechanism By Which Cells Resist Chemotherapy." ScienceDaily. ScienceDaily, 5 March 2007. <www.sciencedaily.com/releases/2007/03/070302111123.htm>.
Universitat Autonoma de Barcelona. (2007, March 5). Researchers Find A Mechanism By Which Cells Resist Chemotherapy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/03/070302111123.htm
Universitat Autonoma de Barcelona. "Researchers Find A Mechanism By Which Cells Resist Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2007/03/070302111123.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins